Personality Change Study for Borderline Personality Disorder
Launched by SHANNON E. SAUER-ZAVALA · Aug 16, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The "Personality Change Study for Borderline Personality Disorder" is looking for individuals with borderline personality disorder to participate in a clinical trial. This study aims to understand how effective a specific treatment can be in helping manage symptoms of the disorder. To start, participants will go through a 2 to 4-week assessment period without any treatment. This will help researchers measure their symptoms before starting the treatment. After this period, participants will attend six weekly sessions, each lasting about 50 to 60 minutes. After completing the sessions, there will be a 4-week follow-up to see how well the treatment worked and if the benefits last over time.
To be eligible for this study, participants need to be fluent in English and have a confirmed diagnosis of borderline personality disorder. However, those who have other psychological issues that might require different treatments, are currently in therapy, have unstable medication, or struggle with substance use disorders will not be able to join. This trial is currently recruiting individuals aged 65 to 74, and both men and women can participate. It's a chance for those who are eligible to contribute to research that could lead to better treatment options for borderline personality disorder.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Speak English fluently
- • Diagnosis of Borderline Personality Disorder
- Exclusion Criteria:
- • diagnosed psychological conditions that would be better addressed by alternative treatments
- • concurrent psychotherapy
- • medication instability
- • substance use disorder
About Shannon E. Sauer Zavala
Shannon E. Sauer-Zavala is a distinguished clinical trial sponsor recognized for her commitment to advancing mental health research and therapeutic interventions. With a robust background in clinical psychology and a focus on innovative treatment methodologies, she leads initiatives that aim to enhance patient outcomes and contribute to the scientific understanding of psychological disorders. Her collaborative approach fosters partnerships with research institutions and healthcare providers, ensuring that trials are designed with rigor and ethical integrity. Through her leadership, Shannon is dedicated to translating research findings into practical applications that benefit diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Patients applied
Trial Officials
Shannon Sauer-Zavala, PhD
Principal Investigator
University of Kentucky
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported